Literature DB >> 30439297

Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section II: Tools for Assessing the Severity of Atopic Dermatitis.

Melinda J Gooderham, Robert Bissonnette, Parbeer Grewal, Perla Lansang, Kim A Papp, Chih-Ho Hong.   

Abstract

Clinicians rely on clinical measures to define the severity of atopic dermatitis and assess outcomes of therapy. These measures can be objective (ie, physician assessments of disease severity) or subjective (ie, patient-reported symptoms and quality of life outcomes). In this review, the most commonly used tools for assessing atopic dermatitis severity in adult patients are presented and compared. These include Eczema Area and Severity Index (EASI); SCORing Atopic Dermatitis (SCORAD); Physician Global Assessment (PGA); body surface area (BSA); Atopic Dermatitis Severity Index (ADSI); Six Area, Six Sign Atopic Dermatitis (SASSAD); Patient Oriented Eczema Measure (POEM); Dermatology Life Quality Index (DLQI); and pruritus Numerical Rating Scale (NRS). Available severity strata for the tools are summarized, although the use of severity strata in clinical practice is not recommended. Since both objective and subjective assessments of disease severity are important to assess, consideration of clinical characteristics such as disease recurrence or persistence, as well as location of the affected areas, should be considered in the overall judgement of disease severity and consideration of therapy choice.

Entities:  

Keywords:  assessment tools; atopic dermatitis; investigator-reported outcomes; patient-reported outcomes; severity

Mesh:

Year:  2018        PMID: 30439297     DOI: 10.1177/1203475418803628

Source DB:  PubMed          Journal:  J Cutan Med Surg        ISSN: 1203-4754            Impact factor:   2.092


  5 in total

1.  Factors Associated with Affective Symptoms and Quality of Life in Patients with Atopic Dermatitis.

Authors:  Silvia Mariel Ferrucci; Simona Tavecchio; Luisa Angileri; Teresa Surace; Emilio Berti; Massimiliano Buoli
Journal:  Acta Derm Venereol       Date:  2021-11-10       Impact factor: 3.875

2.  Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies.

Authors:  Marjolein De Bruin-Weller; Tilo Biedermann; Robert Bissonnette; Mette Deleuran; Peter Foley; Giampiero Girolomoni; Jana Hercogová; Chih-Ho Hong; Norito Katoh; Andrew E Pink; Marie-Aleth Richard; Stephen Shumack; Juan F Silvestre; Stephan Weidinger
Journal:  Acta Derm Venereol       Date:  2021-02-17       Impact factor: 3.875

3.  Management of Atopic Dermatitis in Adults in Saudi Arabia: Consensus Recommendations from the Dermatological Expert Group.

Authors:  Abdullah Alakeel; Afaf Al Sheikh; Ali A Alraddadi; Khalid Mohammed Alattas; Maha Aldayel; Mohammed Abdulaziz Alajlan; Mohammed Al-Haddab; Mohammad Almohideb; Mohamed Fatani; Issam R Hamadah; Ruaa Alharithy; Yousef Binamer; Kim Papp; Ahmed Elaraby
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-07-26

Review 4.  Global Guidelines in Dermatology Mapping Project (GUIDEMAP), a systematic review of atopic dermatitis clinical practice guidelines: are they clear, unbiased, trustworthy and evidence based (CUTE)?

Authors:  Bernd W M Arents; Esther J van Zuuren; Sofieke Vermeulen; Jan W Schoones; Zbys Fedorowicz
Journal:  Br J Dermatol       Date:  2022-05       Impact factor: 11.113

5.  Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial.

Authors:  Yan Zhao; Litao Zhang; Yangfeng Ding; Xiaohua Tao; Chao Ji; Xiuqin Dong; Jianyun Lu; Liming Wu; Rupeng Wang; Qianjin Lu; Aik Han Goh; Rongjun Liu; Zhiguo Zhang; Jianzhong Zhang
Journal:  Am J Clin Dermatol       Date:  2021-08-09       Impact factor: 7.403

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.